Tagged with

Baxter Chile Baxter Chile established itself in the country through the acquisition of a local manufacturer in 1995. What have been the main challenges for the company as a local manufacturer? Chile is a market with many opportunities. For Baxter in Chile, our biggest challenge is maintaining a competitive pricing strategy while…

Farmindustria & Laboratorio Volta As the CEO of Farmindustria since 1998, what would you say has been your recipe for the impressive success that the company has experienced, considering that Farmindustria represents 35% of all contract manufacturing activities in Chile? Our strongest key to success has certainly been the team that work’s here. Manufacturing…

Astellas Poland You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother companies Yamanouchi and Fujisawa. Could you describe to our readers the evolution of the affiliate since the merger? Astellas has…

Bristol-Myers Squibb Poland As Squibb Corporation and Bristol-Myers merged in 1989, Bristol-Myers Squibb has been officially operating in this market since that date, but the affiliate has a long history previous to that. What is the importance of Poland today for the group’s global strategy? About six years ago, there was a need…

Merck Chile What have been Merck’s major milestones and achievements for its pharmaceutical division since you took the reins? I have been managing the Pharma division of Merck since 2006 and the biggest milestone since then has definitely been the acquisition of Serono. In Chile Serono was previously represented by a local…

GC-2 As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up to speed about your company and tell me the story behind GC2 and your role? GC2 is now on its…

LFB In the wake of the most recent CSIS meeting, LFB and Sanofi-Aventis announced the intention to collaborate in bioproduction. What are the terms to this agreement and what are the objectives? On April 2010, the sanofi-aventis group and the LFB group have signed a partnership agreement in France and are…

Shire Brazil We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there a different approach required in the specific area of HGT? For HGT, one very important element is the basic regulatory…

Daiichi Sankyo Germany DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example of this development is your manufacturing facility in Pfaffenhofen, a basis to export to more than 50 countries. Can you…

Teva France We have had the chance to interview a number of Teva’s subsidiaries in Europe, and witnessed how each of them has dealt with the strong transformations that the group has experienced in the last four years. For instance, Mr. Dethlefs from Teva Germany highlighted the challenge in harmonizing five different…

Nycomed France Nycomed lost an important patent with Pantoprazole in the middle of 2009, which has undoubtedly warranted some restructuring. What has been the impact of this loss on business in France, and how are you preparing for the future? Losing exclusivity with Pantoprazole is huge as it was 70% of our…

Quintiles Brazil Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that time, and what does Brazil represent for Quintiles? Brazil is a top 3 priority right now for Quintiles. The first…